ClinicalTrials.gg

Program

Methotrexate

Also written as “methotrexate”, “Methotrexate (MTX)” and “MTX”.

Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Gout · Arthritis, Psoriatic · Arthritis, Juvenile, led by 24 companies.

Furthest: phase 4, since Apr 18, 200793 company-led studies, 4 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche360 open or runningphase 4since Apr 18, 2007Oct 21, 2005none ahead
Bristol-Myers Squibb91 open or runningphase 4since Sep 4, 2015Jul 19, 2005none ahead
Pfizer80 open or runningphase 4since Sep 8, 2005Sep 8, 2005none ahead
AbbVie60 open or runningphase 4since May 25, 2010Sep 13, 2005none ahead
Johnson & Johnson60 open or runningphase 3since Dec 11, 2005Dec 11, 2005none ahead
Aldeyra Therapeutics31 open or runningphase 3since Oct 21, 2019Oct 21, 2019Dec 2029phase 3 · NCT07402876
AstraZeneca30 open or runningphase 4since Aug 23, 2023Sep 16, 2005none ahead
medac31 open or runningphase 3since Jan 11, 2024May 14, 2013Nov 2026phase 3 · NCT06239311
Merck30 open or runningphase 3since Aug 18, 2006Aug 18, 2006none ahead
Halozyme Therapeutics20 open or runningphase 2since Jun 4, 2012Jun 4, 2012none ahead
Amneal Pharmaceuticals10 open or runningphase 1since Sep 15, 2016Sep 15, 2016none ahead
Azidus Brasil10 open or runningphase 2since Apr 15, 2020Apr 15, 2020none ahead
Biocad10 open or runningphase 3since Apr 4, 2016Apr 4, 2016none ahead
Biogen10 open or runningphase 4since May 27, 2005May 27, 2005none ahead
Celltrion10 open or runningphase 1since May 22, 2013May 22, 2013none ahead
Chong Kun Dang Pharmaceutical10 open or runningphase 4since Dec 4, 2012Dec 4, 2012none ahead
forsight-vision410 open or runningphase 2since Apr 24, 2014Apr 24, 2014none ahead
gema-biotech-s-a10 open or runningphase 3since Apr 21, 2016Apr 21, 2016none ahead
jeffrey-j-crowley-md10 open or runningphase 3since Jul 12, 2017Jul 12, 2017none ahead
mediquest-therapeutics10 open or runningphase 2since Apr 22, 2008Apr 22, 2008none ahead
nordic-pharma-sas10 open or runningphase 3since Sep 16, 2015Sep 16, 2015none ahead
prof-kristian-reich10 open or runningphase 3since Jul 26, 2016Jul 26, 2016none ahead
Sanofi10 open or runningphase 3since Nov 13, 2014Nov 13, 2014none ahead
xbiotech-inc11 open or runningphase 2since Aug 22, 2024Aug 22, 2024Jan 15, 2027phase 2 · NCT06590090

Also a collaborator on its studies: Lakefront Biotherapeutics NV, roche-pharma-ag, Regeneron Pharmaceuticals, integrated-therapeutics-group, accutest-research-laboratories-i-pvt-ltd, ppd-development-lp, UCB, immunex-corporation, basilea-pharmaceutica-international-ltd, Tanabe Pharma, astellas-pharma-us-inc and Eisai.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 47 studies since Aug 18, 2009.

  1. May 15, 2017Phase 3 study in Arthritis, RheumatoidHoffmann-La Roche · NCT03155347 · 340 enrolled · China
  2. Jul 12, 2017jeffrey-j-crowley-md's first study: phase 3 study in PsoriasisNew to jeffrey-j-crowley-mdjeffrey-j-crowley-md · NCT03217734 · 56 enrolled · United States
  3. Oct 21, 2019Aldeyra Therapeutics's first study: phase 3 study in Vitreoretinopathy, ProliferativeNew to Aldeyra TherapeuticsAldeyra Therapeutics · NCT04136366 · 106 enrolled · United States
  4. Feb 11, 2020Phase 1 study in Healthy VolunteerBristol-Myers Squibb · NCT04268394 · 48 enrolled · United Kingdom
  5. Apr 15, 2020Azidus Brasil's first study: phase 2 study in COVID-19New to Azidus BrasilAzidus Brasil · NCT04352465 · 42 enrolled · Brazil
  6. May 28, 2021Phase 3 study in Arthritis, RheumatoidBristol-Myers Squibb · NCT04909801 · 338 enrolled · United States, Argentina, Australia and more
  7. Mar 28, 2022Phase 2 study in Retinitis PigmentosaAldeyra Therapeutics · NCT05392179 · 8 enrolled · United States
  8. Jun 30, 2022Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT05445440 · 30 enrolled · United States
  9. Nov 7, 2022Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT05615012 · 76 enrolled · United States
  10. Aug 23, 2023Phase 4 study in HypophosphatasiaAstraZeneca · NCT06015750
  11. Jan 11, 2024Phase 3 study in Moderate to Severe Atopic Dermatitismedac · NCT06239311 · 277 planned · Czechia, France, Italy and more
  12. Aug 22, 2024xbiotech-inc's first study: phase 2 study in Arthritis, RheumatoidNew to xbiotech-incxbiotech-inc · NCT06590090 · 108 planned
  13. Jan 29, 2026Phase 3 study in Primary Vitreoretinal LymphomaAldeyra Therapeutics · NCT07402876 · 20 planned · United States
  14. Nov 16, 2026Primary completion moved from 2026-12 to 2029-12Date moved laterphase 3 · +36 months · NCT07402876

Ahead

  1. Nov 2026Primary completion: phase 3 study in Moderate to Severe Atopic Dermatitismedac · NCT06239311
  2. Jan 15, 2027Primary completion: phase 2 study in Arthritis, Rheumatoidxbiotech-inc · NCT06590090
  3. Dec 2029Primary completion: phase 3 study in Primary Vitreoretinal LymphomaAldeyra Therapeutics · NCT07402876

TargetBeta

DHFR →read by rule
“Dihydrofolate reductase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule

Other programs on DHFR

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
pralatrexateruleAurobindo Pharmaphase 419

Studies

The newest 60 of 93 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07402876Primary Vitreoretinal Lymphoma · United States3RecruitingAldeyra TherapeuticsDec 202920
NCT06590090Arthritis, Rheumatoid2Not yet recruitingxbiotech-incJan 15, 2027108
NCT06239311Moderate to Severe Atopic Dermatitis · Czechia, France, Italy and more3RecruitingmedacNov 2026277
NCT06015750Hypophosphatasia4WithdrawnAstraZenecaMar 13, 20300
NCT05615012Healthy Participants · United States1CompletedBristol-Myers SquibbDec 13, 202376
NCT05445440Healthy Participants · United States1CompletedBristol-Myers SquibbNov 17, 202230
NCT05392179Retinitis Pigmentosa · United States2CompletedAldeyra TherapeuticsJun 23, 20238
NCT04909801Arthritis, Rheumatoid · United States, Argentina, Australia and more3Active, not recruitingBristol-Myers SquibbJun 14, 2023338
NCT04352465COVID-19 · Brazil2UNKNOWNAzidus BrasilJun 30, 202042
NCT04268394Healthy Volunteer · United Kingdom1CompletedBristol-Myers SquibbJun 2, 202148
NCT04136366Vitreoretinopathy, Proliferative · United States3CompletedAldeyra TherapeuticsJun 14, 2022106
NCT03217734Psoriasis · United States3Completedjeffrey-j-crowley-mdDec 31, 201856
NCT03155347Arthritis, Rheumatoid · China3CompletedHoffmann-La RocheAug 8, 2022340
NCT02940561Psoriasis · India1UNKNOWNAmneal PharmaceuticalsOct 201648
NCT02902861Psoriasis Vulgaris · Germany3Completedprof-kristian-reichSep 2014120
NCT02831855Arthritis, Rheumatoid · United States, Australia, Belgium and more4CompletedPfizerNov 19, 2018694
NCT02814175Arthritis, Psoriatic · United States, Australia, Brazil and more4CompletedAbbVieSep 23, 2019246
NCT03332719Arthritis, Rheumatoid · Argentina3Completedgema-biotech-s-aMar 2017168
NCT02744196Arthritis, Rheumatoid3CompletedBiocadFeb 2017159
NCT02699710Healthy Volunteer · United Kingdom1CompletedHoffmann-La RocheMay 26, 201650
NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more2CompletedHoffmann-La RocheAug 2002161
NCT02553018Arthritis, Rheumatoid · France3Completednordic-pharma-sasAug 2017278
NCT02557100Arthritis, Rheumatoid · United States, Canada, Mexico4CompletedBristol-Myers SquibbMar 28, 201980
NCT02504268Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbJan 16, 2017994
NCT02293902Arthritis, Rheumatoid · Japan3CompletedSanofiOct 2016243
NCT02277444Arthritis, Juvenile · United States, Argentina, Brazil and more3CompletedJohnson & JohnsonJul 9, 2018130
NCT02196701Psoriasis3CompletedAbbVieMar 17, 201746
NCT02187055Rhematoid Arthritis · United States, Argentina, Australia and more4CompletedPfizerDec 20161,152
NCT02125266Uveitis, Posterior · United States2Terminatedforsight-vision4Oct 20147
NCT02097173Psoriasis · United States1CompletedmedacOct 201335
NCT02006706Arthritis, Rheumatoid · Serbia3CompletedHoffmann-La RocheNov 23, 200715
NCT01987479Arthritis, Rheumatoid · Netherlands3CompletedHoffmann-La RocheMay 26, 2016150
NCT01995201Arthritis, Rheumatoid · Ireland, Portugal, Spain3CompletedHoffmann-La RocheJul 2015401
NCT01941095Arthritis, Rheumatoid · Greece3CompletedHoffmann-La RocheJul 10, 2016100
NCT01878318Arthritis, Rheumatoid4WithdrawnHoffmann-La RocheJun 20150
NCT01873443Arthritis, Rheumatoid · Korea, Republic of1CompletedCelltrionOct 201487
NCT01871961Arthritis, Rheumatoid · United States1CompletedmedacFeb 2013105
NCT01855789Arthritis, Rheumatoid · United States3CompletedHoffmann-La RocheOct 14, 2016718
NCT01746680Arthritis, Rheumatoid · Korea, Republic of4CompletedChong Kun Dang PharmaceuticalJun 2015111
NCT01737944Arthritis, Rheumatoid · United States2CompletedHalozyme TherapeuticsMay 201138
NCT01661140Arthritis, Rheumatoid · United Kingdom4TerminatedHoffmann-La RocheFeb 2015427
NCT01645280Arthritis, Rheumatoid · United States, Argentina, Bulgaria and more2CompletedJohnson & JohnsonDec 2013274
NCT01618968Arthritis, Rheumatoid · United States2CompletedHalozyme TherapeuticsAug 201249
NCT01587989Arthritis, Rheumatoid · Austria3CompletedHoffmann-La RocheFeb 201477
NCT01399697Arthritis, Rheumatoid · Spain4CompletedHoffmann-La RocheMay 2014261
NCT01353859Arthritis, Rheumatoid · Indonesia3CompletedHoffmann-La RocheJul 201239
NCT01347983Arthritis, Rheumatoid · Taiwan3CompletedHoffmann-La RocheMar 201372
NCT01258712Arthritis, Rheumatoid · Taiwan3CompletedHoffmann-La RocheOct 201286
NCT01235507Arthritis, Rheumatoid · Bosnia and Herzegovina3CompletedHoffmann-La RocheDec 201271
NCT01185301Arthritis, Rheumatoid · United States, Argentina, Austria and more3CompletedAbbVieSep 2012395
NCT01185288Arthritis, Rheumatoid · United States, Puerto Rico4CompletedAbbVieJan 2013309
NCT01163747Arthritis, Rheumatoid · United States4CompletedHoffmann-La RocheDec 201191
NCT01142726Arthritis, Rheumatoid · United States, Australia, Belgium and more3CompletedBristol-Myers SquibbSep 2013511
NCT01162421Arthritis, Rheumatoid4CompletedAbbVieJul 201577
NCT01063062Arthritis, Rheumatoid · Egypt3CompletedHoffmann-La RocheJan 17, 2011107
NCT01034137Arthritis, Rheumatoid · Netherlands3CompletedHoffmann-La RocheSep 2014317
NCT01007435Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedHoffmann-La RocheMay 31, 20121,162
NCT01000610Arthritis, Rheumatoid · Tunisia4CompletedHoffmann-La RocheMay 16, 201218
NCT00973479Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedJohnson & JohnsonMar 2011592
NCT00965653Arthritis, Rheumatoid · Canada, New Zealand, Spain1CompletedHoffmann-La Roche29

How it is read

Names in the registry

  • “Methotrexate”, 71 entries
  • “methotrexate”, 28 entries
  • “Methotrexate (MTX)”, 7 entries
  • “MTX”, 4 entries
  • “methotrexate (MTX)”, 3 entries

Codes read as this program: ADX2191.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.